Free Trial
OTCMKTS:FSNUY

Fresenius SE & Co. 5/8/2024 Earnings Report

Fresenius SE & Co. logo
$14.03 +0.15 (+1.08%)
As of 03:59 PM Eastern

Fresenius SE & Co. EPS Results

Actual EPS
$0.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Fresenius SE & Co. Revenue Results

Actual Revenue
$6.19 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Fresenius SE & Co. Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Fresenius SE & Co.'s next earnings date is estimated for Wednesday, November 5, 2025, based on past reporting schedules.

Conference Call Resources

Fresenius SE & Co. Earnings Headlines

Is *BSEM* Oversold??
BioStem Technologies Inc. (OTC: BSEM) is emerging as one of the most exciting MedTech stories of 2025. The company delivered record-breaking revenues in 2024 and Q1 2025, including $72.5 million in net revenue for Q1 — a 73% increase over the prior year — and six consecutive quarters of positive adjusted EBITDA. With cash reserves rising to $30.8 million and a growing patent portfolio of 58 issued and 68 pending patents, BSEM is scaling profitably while advancing its proprietary BioREtain® technology, which has shown clinically superior results for chronic, non-healing wounds. National recognition is adding to the momentum, with CEO Jason Matuszewski named EY Entrepreneur of the Year 2025 Florida Award winner, validating the leadership driving this high-growth MedTech powerhouse.tc pixel
See More Fresenius SE & Co. Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fresenius SE & Co.? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fresenius SE & Co. and other key companies, straight to your email.

About Fresenius SE & Co.

Fresenius SE & Co. (OTCMKTS:FSNUY) KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co. brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments. Fresenius Medical Care is the largest provider of renal care products and services, including dialysis machines, disposables and clinic operations. Fresenius Kabi offers a broad range of lifesaving medicines, infusion therapies, clinical nutrition and medical devices for intravenous drug delivery. Fresenius Helios manages a network of acute care hospitals and outpatient facilities across Europe, while Fresenius Vamed specializes in planning, construction and management of healthcare projects and facilities, supporting clients from conception through operation.

Fresenius serves patients and healthcare providers in more than 100 countries, with production sites, research centers and clinical operations spanning Europe, North America, Asia-Pacific and Latin America. The company emphasizes continuous innovation, investing in research and development to enhance patient outcomes and streamline care delivery. Under the leadership of Chief Executive Officer Dr. Stephan Sturm, Fresenius pursues a strategy of geographic expansion and portfolio optimization to address evolving global healthcare needs.

View Fresenius SE & Co. Profile

More Earnings Resources from MarketBeat